search
Back to results

A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women (IMARA-SA)

Primary Purpose

Sexually Transmitted Infections, HIV Infections

Status
Active
Phase
Not Applicable
Locations
South Africa
Study Type
Interventional
Intervention
IMARA (intervention group)
Health promotion control group
Sponsored by
University of Illinois at Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Sexually Transmitted Infections focused on measuring HIV prevention, Adolescent girls and young women, South Africa, Mother-daughter intervention

Eligibility Criteria

15 Years - 19 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion criteria for AGYW include:

  • female;
  • 15-19 years-old;
  • residing in Klipfontein/Mitchells Plain (K/MP);
  • speak isiXhosa or English or a combination of these languages;
  • willing to have biometric data collected.

Inclusion criteria for FC include:

  • identified by AGYW as a FC;
  • 24 years and older;
  • living with or in daily contact with the AGYW;
  • speak isiXhosa or English or a combination of these languages;
  • willing to have biometric data collected.

Exclusion Criteria:

  • AGYW will be excluded from the study if they do not have a FC to participate in the study.
  • AGYW and FC will be excluded from the study if they are: a) unable to understand the consent/assent process and provide written informed consent; b) currently enrolled in another research study addressing HIV/STIs/PrEP.
  • AGYW and FC must agree to participate as a dyad. AGYW refusal will supersede FC consent.

Sites / Locations

  • Desmond Tutu Health Foundation

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

IMARA intervention arm

Health promotion control arm

Arm Description

Participants randomized to the IMARA arm will receive the IMARA intervention (i.e., the intervention group).

Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).

Outcomes

Primary Outcome Measures

Proportion of adolescent girls and young women (AGYW) with a sexually-transmitted infection (STI) at baseline and midline
A positive test for at least one of three STIs: chlamydia, gonorrhea, and/or trichomoniasis
Proportion of AGYW who complete HIV testing and counseling (HTC) at baseline and midline
Completion of HTC
Proportion of AGYW who elect to take pre-exposure prophylaxis (PrEP) at baseline and midline
Uptake of PrEP

Secondary Outcome Measures

Proportion of AGYW with an STI at baseline and endline
A positive test for at least one of three STIs: chlamydia, gonorrhea, and/or trichomoniasis
Proportion of AGYW who complete HTC at baseline and endline
Completion of HTC
Proportion of AGYW who elect to take PrEP at baseline and endline
Uptake of PrEP
Proportion of AGYW who report risky sexual behavior at baseline, midline, and endline
Sexual behavior (e.g., condom use, substance use during sex, number of partners, concurrent partners) will be measured via self-report using the AIDS Risk Behavior Assessment (ARBA) (Donenberg, 2001).
Proportion of AGYW who report adherence to PrEP at baseline, midline, and endline
Adherence to PrEP (where appropriate) will be measured via self-report using items from the Wilson scale (2017)
Proportion of AGYW who report adherence to antiretroviral therapy (ART) at baseline, midline, and endline
Adherence to ART (where appropriate) will be measured via self-report using items from the Wilson scale (2017)
Proportion of AGYW who test positive for HIV at baseline, midline, and endline
A positive test for HIV during HTC
Intervention cost-effectiveness
The cost-effectiveness ratio, defined as the incremental cost of the IMARA intervention per infection prevented by the intervention.

Full Information

First Posted
February 11, 2021
Last Updated
September 14, 2023
Sponsor
University of Illinois at Chicago
Collaborators
Desmond Tutu Health Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT04758390
Brief Title
A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women
Acronym
IMARA-SA
Official Title
Multilevel Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 2, 2021 (Actual)
Primary Completion Date
August 31, 2024 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Illinois at Chicago
Collaborators
Desmond Tutu Health Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To achieve an AIDS-free generation, there is a critical need for programs which go beyond individual-level behavior change to reduce HIV and STI infections among adolescent girls and young women in sub-Saharan Africa. Informed, Motivated, Aware, and Responsible Adolescents and Adults (IMARA) is an evidence-based HIV-prevention intervention for adolescent girls and young women (AGYW) and their female caregivers, which has been adapted for a South African audience. The study will test whether AGYW receiving IMARA will have fewer sexually-transmitted infections (STI) and greater acceptance of HIV testing and counseling (HTC) and pre-exposure prophylaxis (PrEP) at 6-month follow-up compared to AGYW assigned to the health-promotion control intervention.
Detailed Description
Reducing new HIV and STI infections among South African (SA) adolescent girls and young women (AGYW) is global public health priority. SA has the world's largest HIV epidemic, and SA AGYW acquire HIV at twice the rate of and seroconvert on average 5 - 7 years earlier than male peers. As new infections continue to outpace access to and availability of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART), primary prevention remains the most viable strategy to stem new transmission. SA efforts to prevent HIV transmission in youth focus mostly on individual-level behavior change, but AGYW's persistent HIV disparities are explained by broad social and structural inequities that shape and constrain HIV-risk behaviors. Comprehensive HIV prevention packages that are integrated, synergistic, and tailored to the local epidemiology and cultural context are likely to achieve and sustain maximum reductions in HIV-risk. Female caregivers (FC) are an untapped resource in the HIV prevention toolbox and offer a novel opportunity to strengthen AGYW prevention efforts. AGYW may also be change agents for their FC who want to be positive role models for AGYW, and thus, adopt HIV prevention behaviors, including HTC and PrEP. This study will evaluate the effectiveness and cost-effectiveness of Informed Motivated Aware and Responsible Adolescents and Adults (IMARA), a multilevel, innovative, family-based HIV prevention program that targets individual, social, and structural drivers of risk. IMARA demonstrated a 43% reduction in incident STI at 12-month follow-up among black 14-18-year-old girls in the US. IMARA has been systematically tailored for the SA context and piloted among AGYW and FC dyads. A two-arm RCT will now be conducted with about 525 AGYW (15-19 years old) and FC dyads. Following randomization, AGYW-FC dyads will participate in a 2-day group workshop (~12 hours) that includes joint and separate mother and daughter activities. AGYW and FC will complete baseline, 6-, and 12-month assessments, including testing for three STI (chlamydia, gonorrhea, and trichomoniasis). We will offer HTC and PrEP at each assessment and track uptake and linkage to care. AGYW and FC who are HIV-negative and interested in PrEP will receive a one-month supply and referral to a clinic. They will additionally receive treatment and counseling if testing positive for an STI and referral for care at an ART clinic if testing positive for HIV. Data will be collected to determine the costs of IMARA. Analyses will compare AGYW across the intervention and control programs on STI incidence, and PrEP and HTC uptake, in addition to secondary outcomes. We will also evaluate the costs and cost-effectiveness of IMARA with respect to the acquisition of STI and HIV, where possible considering power limitations. Additionally, the intervention's implementation will be explored. The study answers an urgent need to evaluate the effectiveness and cost-effectiveness of combination HIV prevention packages for AGYW.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sexually Transmitted Infections, HIV Infections
Keywords
HIV prevention, Adolescent girls and young women, South Africa, Mother-daughter intervention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Adolescent girl and young women-female caregiver (AGYW-FC) dyads will be randomized to the IMARA intervention arm or a health promotion control arm matched in time and intensity. IMARA and the health promotion program will be delivered as group interventions.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
1290 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IMARA intervention arm
Arm Type
Experimental
Arm Description
Participants randomized to the IMARA arm will receive the IMARA intervention (i.e., the intervention group).
Arm Title
Health promotion control arm
Arm Type
Experimental
Arm Description
Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
Intervention Type
Behavioral
Intervention Name(s)
IMARA (intervention group)
Intervention Description
The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
Intervention Type
Behavioral
Intervention Name(s)
Health promotion control group
Intervention Description
The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
Primary Outcome Measure Information:
Title
Proportion of adolescent girls and young women (AGYW) with a sexually-transmitted infection (STI) at baseline and midline
Description
A positive test for at least one of three STIs: chlamydia, gonorrhea, and/or trichomoniasis
Time Frame
~6 months (from baseline to midline)
Title
Proportion of AGYW who complete HIV testing and counseling (HTC) at baseline and midline
Description
Completion of HTC
Time Frame
~6 months (from baseline to midline)
Title
Proportion of AGYW who elect to take pre-exposure prophylaxis (PrEP) at baseline and midline
Description
Uptake of PrEP
Time Frame
~6 months (from baseline to midline)
Secondary Outcome Measure Information:
Title
Proportion of AGYW with an STI at baseline and endline
Description
A positive test for at least one of three STIs: chlamydia, gonorrhea, and/or trichomoniasis
Time Frame
~12 months (from baseline to endline)
Title
Proportion of AGYW who complete HTC at baseline and endline
Description
Completion of HTC
Time Frame
~12 months (from baseline to endline)
Title
Proportion of AGYW who elect to take PrEP at baseline and endline
Description
Uptake of PrEP
Time Frame
~12 months (from baseline to endline)
Title
Proportion of AGYW who report risky sexual behavior at baseline, midline, and endline
Description
Sexual behavior (e.g., condom use, substance use during sex, number of partners, concurrent partners) will be measured via self-report using the AIDS Risk Behavior Assessment (ARBA) (Donenberg, 2001).
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Proportion of AGYW who report adherence to PrEP at baseline, midline, and endline
Description
Adherence to PrEP (where appropriate) will be measured via self-report using items from the Wilson scale (2017)
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Proportion of AGYW who report adherence to antiretroviral therapy (ART) at baseline, midline, and endline
Description
Adherence to ART (where appropriate) will be measured via self-report using items from the Wilson scale (2017)
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Proportion of AGYW who test positive for HIV at baseline, midline, and endline
Description
A positive test for HIV during HTC
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Intervention cost-effectiveness
Description
The cost-effectiveness ratio, defined as the incremental cost of the IMARA intervention per infection prevented by the intervention.
Time Frame
The study duration (~2.5 years)
Other Pre-specified Outcome Measures:
Title
Proportion of female caregivers (FC) with an STI at baseline, midline, and endline
Description
A positive test for at least one of three STIs: chlamydia, gonorrhea, and/or trichomoniasis
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Proportion of FC who complete HTC at baseline, midline, and endline
Description
Completion of HTC
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Proportion of FC who elect to take PrEP baseline, midline, and endline
Description
Uptake of PrEP
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Proportion of FC who report risky sexual behavior at baseline, midline, and endline
Description
Sexual behavior (e.g., condom use, substance use during sex, number of partners, concurrent partners) will be measured via self-report using the AIDS Risk Behavior Assessment (ARBA) (Donenberg, 2001)
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Proportion of FC who test positive for HIV at baseline, midline, and endline
Description
A positive test for HIV during HTC
Time Frame
~6 months (from baseline to midline) and ~12 months (from baseline to endline)
Title
Intervention feasibility
Description
Feasibility will be measured through surveys completed by participants and study staff using items adapted from the Johns Hopkins' Applied Mental Health Research (AMHR) implementation science measure (Haroz et al, 2019).
Time Frame
The study duration (~2.5 years)
Title
Intervention acceptability
Description
Acceptability will be measured through surveys completed by participants and study staff using items adapted from the Johns Hopkins' AMHR implementation science measure (Haroz et al, 2019).
Time Frame
The study duration (~2.5 years)
Title
Intervention appropriateness
Description
Appropriateness will be measured through surveys completed by participants and study staff using items adapted from the Johns Hopkins' AMHR implementation science measure (Haroz et al, 2019).
Time Frame
The study duration (~2.5 years)
Title
Intervention reach
Description
Reach will be assessed through surveys completed by participants and study staff using items adapted from the Johns Hopkins' AMHR implementation science measure (Haroz et al, 2019).
Time Frame
The study duration (~2.5 years)
Title
Intervention adoption
Description
Adoption will be assessed through surveys completed by participants and study staff using items adapted from the Antiretroviral Treatment Access Study (ARTAS) (Norton et al, 2012).
Time Frame
The study duration (~2.5 years)
Title
Intervention fidelity
Description
Fidelity will be assessed by facilitators and observers of the intervention using an adapted version of the Treatment Fidelity Questionnaire (Lane et al, 2004).
Time Frame
The study duration (~2.5 years)

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Participants will be eligible to participate if they are female.
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for AGYW include: female; 15-19 years-old; residing in Klipfontein/Mitchells Plain (K/MP); speak isiXhosa or English or a combination of these languages; willing to have biometric data collected. Inclusion criteria for FC include: identified by AGYW as a FC; 24 years and older; living with or in daily contact with the AGYW; speak isiXhosa or English or a combination of these languages; willing to have biometric data collected. Exclusion Criteria: AGYW will be excluded from the study if they do not have a FC to participate in the study. AGYW and FC will be excluded from the study if they are: a) unable to understand the consent/assent process and provide written informed consent; b) currently enrolled in another research study addressing HIV/STIs/PrEP. AGYW and FC must agree to participate as a dyad. AGYW refusal will supersede FC consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Geri R Donenberg, PhD
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Linda-Gail Bekker, MBChB, PhD
Organizational Affiliation
Desmond Tutu Health Foundation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Desmond Tutu Health Foundation
City
Cape Town
ZIP/Postal Code
7925
Country
South Africa

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified data will be placed in one or more electronic databases (e.g. DASH, PATC3H) which could be used for other research studies in addition to this one.
IPD Sharing Time Frame
Data sharing will generally coincide with publication of the study's main findings no later than 1 year after acceptance of the primary manuscript or study closure, whichever comes first.
IPD Sharing Access Criteria
To access data in the DASH repository, users will be required to register in DASH, belong to an institution with an approved assurance from the Department of Health and Human Services Office for Human Research Protections, submit a research plan, execute a DASH data use agreement, submit approval from their local IRB, obtain approval by the DASH Data Access Committee, and obtain approval from the Study-Specific Approving Entity. To access data through the PATC3H consortium, researchers must be on one of the PATC3H consortium research teams; the decision to share data will be at the discretion of the principal investigator.
IPD Sharing URL
https://dash.nichd.nih.gov/
Citations:
PubMed Identifier
33137103
Citation
Donenberg GR, Kendall AD, Emerson E, Fletcher FE, Bray BC, McCabe K. IMARA: A mother-daughter group randomized controlled trial to reduce sexually transmitted infections in Black/African-American adolescents. PLoS One. 2020 Nov 2;15(11):e0239650. doi: 10.1371/journal.pone.0239650. eCollection 2020.
Results Reference
background
Citation
Atujuna M, Merrill K, Ndwayana S, Emerson E, Fynn L, Bekker L-G, Donenberg G: Engaging female caregivers to improve South African girls' and young womens' sexual and reproductive health outcomes. In: HIV Research for Prevention Virtual Conference. 2021.
Results Reference
background
PubMed Identifier
11392341
Citation
Donenberg GR, Emerson E, Bryant FB, Wilson H, Weber-Shifrin E. Understanding AIDS-risk behavior among adolescents in psychiatric care: links to psychopathology and peer relationships. J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):642-53. doi: 10.1097/00004583-200106000-00008.
Results Reference
background
PubMed Identifier
27098408
Citation
Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a New Three-Item Self-Report Measure for Medication Adherence. AIDS Behav. 2016 Nov;20(11):2700-2708. doi: 10.1007/s10461-016-1406-x.
Results Reference
background
PubMed Identifier
31036002
Citation
Haroz EE, Bolton P, Nguyen AJ, Lee C, Bogdanov S, Bass J, Singh NS, Doty B, Murray L. Measuring implementation in global mental health: validation of a pragmatic implementation science measure in eastern Ukraine using an experimental vignette design. BMC Health Serv Res. 2019 Apr 29;19(1):262. doi: 10.1186/s12913-019-4097-y.
Results Reference
background
Citation
Lane KL, Bocian KM, MacMillan DL, Gresham FM. Treatment integrity: An essential-but often forgotten-component of school-based interventions. Preventing School Failure. 2004; 48(3): 36-43.
Results Reference
background
PubMed Identifier
22471965
Citation
Norton WE. An exploratory study to examine intentions to adopt an evidence-based HIV linkage-to-care intervention among state health department AIDS directors in the United States. Implement Sci. 2012 Apr 2;7:27. doi: 10.1186/1748-5908-7-27.
Results Reference
background
PubMed Identifier
34847908
Citation
Donenberg G, Merrill KG, Atujuna M, Emerson E, Bray B, Bekker LG. Mental health outcomes of a pilot 2-arm randomized controlled trial of a HIV-prevention program for South African adolescent girls and young women and their female caregivers. BMC Public Health. 2021 Nov 30;21(1):2189. doi: 10.1186/s12889-021-12010-1.
Results Reference
derived
PubMed Identifier
34544403
Citation
Donenberg GR, Atujuna M, Merrill KG, Emerson E, Ndwayana S, Blachman-Demner D, Bekker LG. An individually randomized controlled trial of a mother-daughter HIV/STI prevention program for adolescent girls and young women in South Africa: IMARA-SA study protocol. BMC Public Health. 2021 Sep 20;21(1):1708. doi: 10.1186/s12889-021-11727-3.
Results Reference
derived

Learn more about this trial

A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women

We'll reach out to this number within 24 hrs